Hogan Lovells advises on HK$611 million IPO and Chapter 18A listing of Cloudbreak Pharma Inc.

Cloudbreak Pharma Inc. is an innovation-driven clinical-stage ophthalmology biotechnology company dedicated to the development of novel and differentiated treatments. It has established a broad and innovative pipeline of numerous drug candidates covering major anterior and posterior ophthalmic diseases, some of which are expected to be first-in-class drug therapies globally for the treatment of various eye diseases.

CCB International Capital Limited and Huatai Financial Holdings (Hong Kong) Limited acted as the Joint Sponsors and Overall Coordinators for the transaction.

Hong Kong corporate partner Sammy Li led the Hogan Lovells team, with support from counsel Samson Suen, senior associate Tiffany Lam and senior paralegal Vivian Siu. New York capital markets partner Richard Aftanas, senior associates David Wallace and Sophie Beutel provided US law advice. Los Angeles regulatory partner Robert Church, senior associate Eman Al-Hassan and associate Will Tenbarge provided US pharmaceutical and biotechnology regulatory legal advice.  

Sammy Li commented: "We’re proud to have supported Cloudbreak Pharma on this successful listing. With our market-leading life sciences practice and deep experience advising biotech companies, Hogan Lovells is uniquely positioned to guide innovative clients through their fundraising journeys in Hong Kong. Our capital markets team is fully committed to helping clients achieve their strategic goals with precision and efficiency."